{"entity":{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","aka":["NeoSTAR"],"tldr":"A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting.","summary":"Sacituzumab Govitecan In TNBC is a phase 2, interventional study registered as NCT04230109 by Massachusetts General Hospital, with a registry enrolment figure of 239 participants, started 2020-07-14 and due to reach its primary completion in 2028-10. Interventions recorded: Sacituzumab Govitecan; Pembrolizumab. Conditions listed: Invasive Breast Cancer; Triple Negative Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; HER2-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04230109","url":"https://clinicaltrials.gov/study/NCT04230109"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["sacituzumab-govitecan","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04230109","phase":"2","setting":"A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)","sponsor":"Massachusetts General Hospital","enrolled":239,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04230109/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}